Your browser doesn't support javascript.
loading
Mixed meal tolerance testing highlights in diabetes altered branched-chain ketoacid metabolism and pathways associated with all-cause mortality.
Mi, Michael Y; Whitlock, Mark; Shi, Xu; Farrell, Laurie A; Bhambhani, Victoria M; Quadir, Juweria; Blatnik, Matthew; Wald, Kyle P; Tierney, Brendan; Kim, Albert; Loudon, Peter; Chen, Zsu-Zsu; Correa, Adolfo; Gao, Yan; Carson, April P; Bertoni, Alain G; Roth Flach, Rachel J; Gerszten, Robert E.
Affiliation
  • Mi MY; Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: mmi@bidmc.harvard.edu.
  • Whitlock M; Early Clinical Development, Pfizer, Cambridge, UK.
  • Shi X; Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Farrell LA; Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Bhambhani VM; Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Quadir J; Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Blatnik M; Early Clinical Development, Pfizer, Groton, CT, USA.
  • Wald KP; Early Clinical Development, Pfizer, Groton, CT, USA.
  • Tierney B; Early Clinical Development, Pfizer, Groton, CT, USA.
  • Kim A; Internal Medicine Research Unit, Pfizer, Cambridge, MA, USA; Cytel, Cambridge, MA, USA.
  • Loudon P; Early Clinical Development, Pfizer, Cambridge, UK; Tenpoint Therapeutics, Cambridge, UK.
  • Chen ZZ; Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Correa A; Department of Population Health Science, University of Mississippi Medical Center, Jackson, MS, USA.
  • Gao Y; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
  • Carson AP; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
  • Bertoni AG; Department of Epidemiology & Prevention, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Roth Flach RJ; Internal Medicine Research Unit, Pfizer, Cambridge, MA, USA.
  • Gerszten RE; Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Am J Clin Nutr ; 117(3): 529-539, 2023 03.
Article in En | MEDLINE | ID: mdl-36811472
BACKGROUND: Elevated BCAA levels are strongly associated with diabetes, but how diabetes affects BCAA, branched-chain ketoacids (BCKAs), and the broader metabolome after a meal is not well known. OBJECTIVE: To compare quantitative BCAA and BCKA levels in a multiracial cohort with and without diabetes after a mixed meal tolerance test (MMTT) as well as to explore the kinetics of additional metabolites and their associations with mortality in self-identified African Americans. METHODS: We administered an MMTT to 11 participants without obesity or diabetes and 13 participants with diabetes (treated with metformin only) and measured the levels of BCKAs, BCAAs, and 194 other metabolites at 8 time points across 5 h. We used mixed models for repeated measurements to compare between group metabolite differences at each timepoint with adjustment for baseline. We then evaluated the association of top metabolites with different kinetics with all-cause mortality in the Jackson Heart Study (JHS) (N = 2441). RESULTS: BCAA levels, after adjustment for baseline, were similar at all timepoints between groups, but adjusted BCKA kinetics were different between groups for α-ketoisocaproate (P = 0.022) and α-ketoisovalerate (P = 0.021), most notably diverging at 120 min post-MMTT. An additional 20 metabolites had significantly different kinetics across timepoints between groups, and 9 of these metabolites-including several acylcarnitines-were significantly associated with mortality in JHS, irrespective of diabetes status. The highest quartile of a composite metabolite risk score was associated with higher mortality (HR:1.57; 1.20, 2.05, P = 0.00094) than the lowest quartile. CONCLUSIONS: BCKA levels remained elevated after an MMTT among participants with diabetes, suggesting that BCKA catabolism may be a key dysregulated process in the interaction of BCAA and diabetes. Metabolites with different kinetics after an MMTT may be markers of dysmetabolism and associated with increased mortality in self-identified African Americans.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Amino Acids, Branched-Chain Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Am J Clin Nutr Year: 2023 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus / Amino Acids, Branched-Chain Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Am J Clin Nutr Year: 2023 Document type: Article Country of publication: United States